Namilumab

DB13037InvestigationalProtein Based Therapies

Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.

Mechanism: Namilumab is a human antibody which neutralizes the activity of granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential applications in the treatment of various inflammatory and autoimmune diseases, such as rheumatoid arthritis, psoriasis, or multiple sclerosis.
Curator reviewed
Also known as: MT203

Resolves to

Compound

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

381Drug interactionsStructured to mechanism, not free text

8Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Namilumab, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.